氢吗啡酮PCIA的背景剂量在腹腔镜胆囊切除术后应用的研究进展

Research Progress on the Application of Background Dose of Hydromorphone PCIA after Laparoscopic Cholecystectomy

摘要: 腹腔镜胆囊切除术虽为微创术式，但术后因切口、胆囊床炎症及膈肌刺激等，约30%~50%患者24小时内会经历中重度疼痛，传统镇痛方法效果欠佳且不良反应多。患者自控静脉镇痛(PCIA)优势显著，而氢吗啡酮作为强效μ阿片受体激动剂，具有起效快、镇痛强、代谢产物无活性等特点，在PCIA中应用价值突出。本文循证评价氢吗啡酮PCIA，其通过激动中枢μ阿片受体发挥镇痛作用，药代动力学支持背景剂量设置需平衡镇痛与不良反应。临床显示其镇痛效果呈剂量依赖性，不良反应随剂量升高而增加，且在患者满意度和功能恢复上表现良好；与传统阿片类药物相比各有优劣，联合区域阻滞技术或多模式镇痛可优化效果；老年、肝肾功能异常、阿片耐受等特殊人群需个体化调整剂量。当前研究存在最佳背景剂量争议、研究异质性大、长期预后数据缺乏等问题，未来需聚焦精准剂量设置、AI辅助镇痛方案及多中心大样本研究。综上，氢吗啡酮PCIA是该术后多模式镇痛的重要组成，术后24小时内可考虑背景输注，后续需个体化调整，临床应用需标准化给药、密切监测并关注特殊人群。

Abstract: Although laparoscopic cholecystectomy is a minimally invasive surgical procedure, approximately 30% to 50% of patients experience moderate to severe pain within 24 hours postoperatively due to incisions, inflammation at the gallbladder bed, and diaphragmatic irritation. Traditional analgesic methods are less effective and associated with many adverse reactions. Patient-controlled intravenous analgesia (PCIA) has significant advantages, and hydromorphone, as a potent μ-opioid receptor agonist, features rapid onset, strong analgesic effect, and inactive metabolites, thus showing prominent application value in PCIA. This article conducts an evidence-based evaluation of hydromorphone-based PCIA: it exerts analgesic effects by activating central μ-opioid receptors, and its pharmacokinetics require balancing analgesia and adverse reactions when setting the background dose. Clinical studies have shown that its analgesic effect is dose-dependent, with adverse reactions increasing as the dose rises; additionally, it performs well in terms of patient satisfaction and functional recovery. Compared with traditional opioid drugs, each has its own advantages and disadvantages, and combining it with regional block techniques or multimodal analgesia can optimize the effect. For special populations such as the elderly, patients with abnormal liver or kidney function, and those with opioid tolerance, individualized dose adjustment is necessary. Current studies have limitations including controversies over the optimal background dose, high research heterogeneity, and lack of long-term prognosis data. Future research should focus on precise dose setting, AI-assisted analgesic regimens, and multi-center large-sample studies. In conclusion, hydromorphone-based PCIA is an important component of multimodal analgesia after laparoscopic cholecystectomy. Background infusion may be considered within 24 hours postoperatively, followed by individualized adjustment. For clinical application, standardized administration, close monitoring, and attention to special populations are required.